Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases - Survey by outcome research network for evaluation of treatment results in oncology

被引:57
作者
Moscetti, Luca
Nelli, Fabrizio [1 ]
Felici, Alessandra
Rinaldi, Massimo
De Santis, Stefano
D'Auria, Giuliana
Mansueto, Giovanni
Tonini, Giuseppe
Sperduti, Isabella
Pollera, Francesco C.
机构
[1] Cent Hosp Belcolle, Dept Med Oncol, Viterbo, Italy
[2] Regina Elena Inst Canc Res, Dept Med Oncol, Rome, Italy
[3] San Camillo Forlanini Hosp, Pulm Oncol Unit 5, Rome, Italy
[4] Univ Roma La Sapienza, Policlin Umberto I, Dept Med Oncol, Rome, Italy
[5] Santissima Trinita Hosp, Dept Med Oncol, Frosinone, Italy
[6] Dept Med Oncol, Rome, Italy
[7] Regina Elena Inst Canc Res, Dept Biostat, Rome, Italy
关键词
brain; chemotherapy; metastasis; nonsmall cell lung cancer; whole-brain radiotherapy;
D O I
10.1002/cncr.22399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. For patients with stage IV nonsmall cell lung cancer (NSCLC) who present with brain metastasis (BMs), standard platinum-based chemotherapy regimens have challenged the role of up-front whole-brain radiotherapy (WBRT). METHODS. in this survey, the authors analyzed the decision tree by which 6 oncologic centers guided the pattern of care in an unselected population of patients with NSCLC who presented with BMs at first diagnosis. The impact of front-line, platinum-based chemotherapy also was evaluated. Individual data were reviewed from 156 eligible patients who were referred to participating centers. RESULTS. Up-front treatment included chemotherapy in 110 patients and WBRT followed by chemotherapy in 46 patients. The selection of first treatment was guided based mainly on the presence of by BM symptoms, with chemotherapy selected for 24% of patients in the chemotherapy cohort and for 76% of patients in the chemotherapy and WBRT cohort. Regardless of treatment, the brain response was 29% (27% and 35% for the chemotherapy and WBRT cohorts, respectively; P value not significant). For the entire population, the overall response rate was 37%, progression-free survival was 6 months, and the median survival was I I months. At multivariate analysis, significant predictors for survival were: brain response (hazard ratio [HR], 2.59; P =.0001), modified Radiation Therapy Oncology Group class (HR, 0.87; P =.003), and Eastern Cooperative Oncology Group performance status (HR, 1.49; P =.04). CONCLUSIONS. For patients with NSCLC who present with BMs at first diagnosis, the results of the current survey confirmed that the expected benefit of platinum-based chemotherapy may be translated into clinical practice and that selected subsets of patients who receive frontline chemotherapy (ie, patients in whom BM symptoms are absent or are controlled by supportive therapy) may be spared from WBRT. Further prospective studies evaluating different approaches and interventions are warranted.
引用
收藏
页码:274 / 281
页数:8
相关论文
共 30 条
[1]   Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer:: A Spanish lung cancer group phase III randomized trial [J].
Alberola, V ;
Camps, C ;
Provencio, M ;
Isla, D ;
Rosell, R ;
Vadell, C ;
Bover, I ;
Ruiz-Casado, A ;
Azagra, P ;
Jiménez, U ;
González-Larriba, JL ;
Diz, P ;
Cardenal, F ;
Artal, A ;
Carrato, A ;
Morales, S ;
Sánchez, JJ ;
de las Peñas, R ;
Felip, E ;
López-Vivanco, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) :3207-3213
[2]   First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: A phase II study [J].
Bernardo, G ;
Cuzzoni, Q ;
Strada, MR ;
Bernardo, A ;
Brunetti, G ;
Jedrychowska, I ;
Pozzi, U ;
Palumbo, R .
CANCER INVESTIGATION, 2002, 20 (03) :293-302
[3]   Treatment of advanced non-small-cell lung cancer with two-drug combinations [J].
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3565-3567
[4]   Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study [J].
Christodoulou, C ;
Bafaloukos, D ;
Linardou, H ;
Aravantinos, G ;
Bamias, A ;
Carina, M ;
Klouvas, G ;
Skarlos, D .
JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (01) :61-65
[5]   Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer [J].
Cortes, J ;
Rodriguez, J ;
Aramendia, JM ;
Salgado, E ;
Gurpide, A ;
Garcia-Foncillas, J ;
Aristu, JJ ;
Claver, A ;
Bosch, A ;
Lopez-Picazo, JM ;
Martin-Algarra, S ;
Brugarolas, A ;
Calvo, E .
ONCOLOGY, 2003, 64 (01) :28-35
[6]   Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:: A randomized phase III study of the Italian lung cancer project [J].
Crinò, L ;
Scagliotti, GV ;
Ricci, S ;
De Marinis, F ;
Rinaldi, M ;
Gridelli, C ;
Ceribelli, A ;
Bianco, R ;
Marangolo, M ;
Di Costanzo, F ;
Sassi, M ;
Barni, S ;
Ravaioli, A ;
Adamo, V ;
Portalone, L ;
Cruciani, G ;
Masotti, A ;
Ferrara, G ;
Gozzelino, F ;
Tonato, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3522-3530
[7]   MANAGEMENT OF BRAIN METASTASES [J].
DEANGELIS, LM .
CANCER INVESTIGATION, 1994, 12 (02) :156-165
[8]  
Doolittle ND, 2005, CLIN CANCER RES, V11, P421
[9]   Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965) [J].
Dziadziuszko, R ;
Ardizzoni, A ;
Postmus, PE ;
Smit, EF ;
Price, A ;
Debruyne, C ;
Legrand, C ;
Giaccone, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (09) :1271-1276
[10]   The treatment of brain metastases from lung cancer [J].
Ellis, R ;
Gregor, A .
LUNG CANCER, 1998, 20 (02) :81-84